AR053186A1 - Derivados del 1- bencil indol carboxamida - Google Patents
Derivados del 1- bencil indol carboxamidaInfo
- Publication number
- AR053186A1 AR053186A1 ARP060101091A ARP060101091A AR053186A1 AR 053186 A1 AR053186 A1 AR 053186A1 AR P060101091 A ARP060101091 A AR P060101091A AR P060101091 A ARP060101091 A AR P060101091A AR 053186 A1 AR053186 A1 AR 053186A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkyloxy
- cycloalkyl
- derivatives
- indole
- Prior art date
Links
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 title 1
- 229910052736 halogen Inorganic materials 0.000 abstract 5
- 150000002367 halogens Chemical class 0.000 abstract 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 4
- 125000003545 alkoxy group Chemical group 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- -1 indole-4-yl Chemical group 0.000 abstract 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- BFHBQXLAAIUPTF-UHFFFAOYSA-N 1-benzylindole-2-carboxamide Chemical class NC(=O)C1=CC2=CC=CC=C2N1CC1=CC=CC=C1 BFHBQXLAAIUPTF-UHFFFAOYSA-N 0.000 abstract 2
- 229910052731 fluorine Inorganic materials 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- 125000006526 (C1-C2) alkyl group Chemical group 0.000 abstract 1
- 125000002861 (C1-C4) alkanoyl group Chemical group 0.000 abstract 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 abstract 1
- 229910052794 bromium Inorganic materials 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Addiction (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Derivados del 1-bencil indol-2-carboxamida de formula (1), en donde R1 es H o F; R2 es H, halogeno, alquilo C1-4, alcoxi C1-4, alquiloxi C1-4, cicloalquilo C3-6 o cicloalquil C3-6-alquilo C1-2, siendo dichos alquilo C1-4 y alquiloxi C1-4 opcionalmente sustituidos con 1 a 3 halogenos o R2 es un anillo heteroarilo de 5 a 6 miembros que contiene 1 o 2 heteroátomos seleccionados entre N y O, o R2 es un anillo heterocíclico saturado de 5 a 6 miembros que contiene una a dos mitades de heteroátomos seleccionados entre O y NR8; R3 es H o F; R4 es H, halogeno, CH3, OCH3, CF3 o junto con R5 y el anillo fenilo R4 forman un indol-4-il o un quinolin-5-il, R5 s halogeno, alquilo C1-4, CF3, alquiloxi C1-4, OCF3 o junto con R4 y el anillo fenilo R5 forman un indol-4-il o un quinolin-5-il; proporcionando que uno a tres de los R1-R5 no sean H; R6 es 1 o 2 sustituyentes seleccionados entre Cl, Br y CN; R7 es alquilo C1-6 opcionalmente sustituido con uno a tres halogenos, cicloalquilo C3- 6 o cicloalquil C3-6-alquilo C1-2, siendo cada uno sustituido con uno o más sustituyentes seleccionados entre hidroxi, hidroxialquilo C1-2, alquiloxi C1-4, tioalquiloxi C1-2, o R7 es C4-6oxacicloalquil-C1-2 alquilo, siendo dicho C1-2 opcionalmente sustituido con un hidroxi o un hidroxi alquilo C1-2, o R7 es C4-6 oxacicloalquilo y R8 es H, alquilo C1-4, acilo C1-4 o una sal o los solvatos farmacéuticamente aceptable de estos. También se relaciona con las composiciones farmacéuticas que comprenden dichos derivados 1-bencil indole-2-carboxamida y sus usos en terapia.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05102217 | 2005-03-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR053186A1 true AR053186A1 (es) | 2007-04-25 |
Family
ID=34939021
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060101091A AR053186A1 (es) | 2005-03-21 | 2006-03-21 | Derivados del 1- bencil indol carboxamida |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US7671080B2 (es) |
| EP (1) | EP1940788A1 (es) |
| JP (1) | JP2008533187A (es) |
| KR (1) | KR20070121757A (es) |
| CN (1) | CN101151246B (es) |
| AR (1) | AR053186A1 (es) |
| AU (1) | AU2006226394B2 (es) |
| BR (1) | BRPI0609773A2 (es) |
| CA (1) | CA2599855A1 (es) |
| IL (1) | IL185674A0 (es) |
| MX (1) | MX2007011366A (es) |
| NO (1) | NO20074441L (es) |
| NZ (1) | NZ561159A (es) |
| PE (1) | PE20061290A1 (es) |
| RU (1) | RU2007138937A (es) |
| TW (1) | TW200700387A (es) |
| UA (1) | UA92000C2 (es) |
| WO (1) | WO2006100208A1 (es) |
| ZA (1) | ZA200707358B (es) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8841334B2 (en) | 2006-05-31 | 2014-09-23 | Abbvie Inc. | Compounds as cannabinoid receptor ligands and uses thereof |
| WO2007140385A2 (en) | 2006-05-31 | 2007-12-06 | Abbott Laboratories | Thiazole compounds as cannabinoid receptor ligands and uses thereof |
| JP2009538933A (ja) | 2006-05-31 | 2009-11-12 | アボット・ラボラトリーズ | カンナビノイド受容体リガンドとしての化合物およびその使用 |
| KR20090047458A (ko) | 2006-08-08 | 2009-05-12 | 사노피-아벤티스 | 아릴아미노아릴-알킬-치환된 이미다졸리딘-2,4-디온, 이의 제조방법, 이들 화합물을 포함하는 약제 및 이의 용도 |
| CN101765594A (zh) | 2007-03-28 | 2010-06-30 | 雅培制药有限公司 | 作为大麻素受体配体的1,3-噻唑-2(3h)-亚基化合物 |
| US7872033B2 (en) | 2007-04-17 | 2011-01-18 | Abbott Laboratories | Compounds as cannabinoid receptor ligands |
| WO2008144360A1 (en) | 2007-05-18 | 2008-11-27 | Abbott Laboratories | Novel compounds as cannabinoid receptor ligands |
| US7943658B2 (en) | 2007-07-23 | 2011-05-17 | Bristol-Myers Squibb Company | Indole indane amide compounds useful as CB2 agonists and method |
| KR20100066422A (ko) * | 2007-08-10 | 2010-06-17 | 하. 룬트벡 아크티에 셀스카브 | 헤테로아릴 아미드 유사체 |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| US9193713B2 (en) | 2007-10-12 | 2015-11-24 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
| WO2009114566A1 (en) | 2008-03-11 | 2009-09-17 | Abbott Laboratories | Novel compounds as cannabinoid receptor ligands |
| UY31968A (es) | 2008-07-09 | 2010-01-29 | Sanofi Aventis | Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos |
| US8846730B2 (en) | 2008-09-08 | 2014-09-30 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
| US8188135B2 (en) | 2008-09-16 | 2012-05-29 | Abbott Laboratories | Compounds as cannabinoid receptor ligands |
| WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
| PA8854001A1 (es) | 2008-12-16 | 2010-07-27 | Abbott Lab | Compuestos novedosos como ligandos de receptores de canabinoides |
| WO2011023754A1 (en) | 2009-08-26 | 2011-03-03 | Sanofi-Aventis | Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
| UY32940A (es) * | 2009-10-27 | 2011-05-31 | Bayer Cropscience Ag | Amidas sustituidas con halogenoalquilo como insecticidas y acaricidas |
| US8933024B2 (en) | 2010-06-18 | 2015-01-13 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
| WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8710050B2 (en) | 2011-03-08 | 2014-04-29 | Sanofi | Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| US8828994B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| WO2012120053A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP3946606B1 (en) | 2019-03-27 | 2025-01-01 | Insilico Medicine IP Limited | Bicyclic jak inhibitors and uses thereof |
| BR112022010561A2 (pt) | 2019-12-02 | 2022-11-16 | Storm Therapeutics Ltd | Compostos poli-heterocíclicos como inibidores de mettl3 |
| TWI871635B (zh) * | 2023-05-18 | 2025-02-01 | 龍華科技大學 | 創新的高氧磁化量子化飲用水處理製程方法 |
| CN118772003B (zh) * | 2024-06-12 | 2025-03-28 | 济宁市第一人民医院(济宁市医学科学研究院) | (S)-β-氨基异丁酸酯及其制备方法和在肥胖症中的应用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2399791A1 (en) * | 2000-02-11 | 2001-08-16 | Bristol-Myers Squibb Company | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases |
-
2006
- 2006-03-09 TW TW095107975A patent/TW200700387A/zh unknown
- 2006-03-17 JP JP2008502383A patent/JP2008533187A/ja not_active Withdrawn
- 2006-03-17 KR KR1020077023732A patent/KR20070121757A/ko not_active Withdrawn
- 2006-03-17 UA UAA200709943A patent/UA92000C2/ru unknown
- 2006-03-17 US US11/908,640 patent/US7671080B2/en not_active Expired - Fee Related
- 2006-03-17 BR BRPI0609773-1A patent/BRPI0609773A2/pt not_active IP Right Cessation
- 2006-03-17 CA CA002599855A patent/CA2599855A1/en not_active Abandoned
- 2006-03-17 CN CN2006800107017A patent/CN101151246B/zh not_active Expired - Fee Related
- 2006-03-17 MX MX2007011366A patent/MX2007011366A/es active IP Right Grant
- 2006-03-17 NZ NZ561159A patent/NZ561159A/en not_active IP Right Cessation
- 2006-03-17 RU RU2007138937/04A patent/RU2007138937A/ru not_active Application Discontinuation
- 2006-03-17 WO PCT/EP2006/060821 patent/WO2006100208A1/en not_active Ceased
- 2006-03-17 AU AU2006226394A patent/AU2006226394B2/en not_active Ceased
- 2006-03-17 EP EP06725123A patent/EP1940788A1/en not_active Withdrawn
- 2006-03-20 PE PE2006000306A patent/PE20061290A1/es not_active Application Discontinuation
- 2006-03-21 AR ARP060101091A patent/AR053186A1/es unknown
-
2007
- 2007-08-29 ZA ZA200707358A patent/ZA200707358B/xx unknown
- 2007-09-03 NO NO20074441A patent/NO20074441L/no not_active Application Discontinuation
- 2007-09-03 IL IL185674A patent/IL185674A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2006226394A1 (en) | 2006-09-28 |
| JP2008533187A (ja) | 2008-08-21 |
| RU2007138937A (ru) | 2009-04-27 |
| US20080280923A1 (en) | 2008-11-13 |
| EP1940788A1 (en) | 2008-07-09 |
| AU2006226394B2 (en) | 2011-08-18 |
| NZ561159A (en) | 2009-10-30 |
| IL185674A0 (en) | 2008-01-06 |
| ZA200707358B (en) | 2009-08-26 |
| UA92000C2 (en) | 2010-09-27 |
| MX2007011366A (es) | 2007-10-03 |
| NO20074441L (no) | 2007-12-07 |
| CN101151246A (zh) | 2008-03-26 |
| KR20070121757A (ko) | 2007-12-27 |
| CA2599855A1 (en) | 2006-09-28 |
| BRPI0609773A2 (pt) | 2011-10-18 |
| CN101151246B (zh) | 2011-04-13 |
| TW200700387A (en) | 2007-01-01 |
| WO2006100208A1 (en) | 2006-09-28 |
| PE20061290A1 (es) | 2006-12-19 |
| US7671080B2 (en) | 2010-03-02 |
| WO2006100208A9 (en) | 2007-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR053186A1 (es) | Derivados del 1- bencil indol carboxamida | |
| PE20221253A1 (es) | Inhibidores de pequenas moleculas de mutante g12c de kras | |
| PE20230238A1 (es) | Inhibidores de kras g12c | |
| AR068846A1 (es) | Compuestos derivados de pirrolo (2,3d)-pirimidina inhibidores de la actividad de pkb, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos como agentes anticancer | |
| AR064547A1 (es) | Derivados de azaspiro como antagonistas del receptor v1a | |
| AR052902A1 (es) | Derivados de piridazina, composicion farmaceutica que los contiene y su uso como agentes terapeuticos para enfermedades mediadas por la estearoil-coa desaturasa | |
| PE20160240A1 (es) | Nuevos derivados de indolizina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| AR073687A1 (es) | Agonistas de receptores cb2, derivados de oxazoles y/o triazoles, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del dolor, enfermedades autoinmunes y alergicas, entre otras. | |
| ES2334565T3 (es) | Agonistas inversos del receptor cb 1. | |
| AR055150A1 (es) | Compuestos de isoindol - imido y composiciones que los comprenden y sus metodos de uso | |
| AR105845A1 (es) | Compuestos de heteroarilo bicíclicos fusionados como moduladores de la función irak4 | |
| AR063015A1 (es) | Derivados de quinazolinona 5-sustituida y composiciones que los comprenden y metodos para utilizarlos en el tratamiento del cancer | |
| AR046711A1 (es) | 5-7-diaminopirazolo[4,3d]pirimidinas como inhibidores de la pde-5,composiciones farmaceuticas que las contienen y usos en el tratamiento de hipertensiones | |
| AR054799A1 (es) | Derivados de oxindol | |
| AR096979A1 (es) | Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR054365A1 (es) | Derivados de heteroaril benzamidas, composiciones farmaceuticas que los contienen, usos en enfermedades mediadas por glucoquinasasy metodo de preparacion de los mismos. | |
| AR076435A1 (es) | Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos | |
| CO6160322A2 (es) | Derivados de quinazolinona e isoquinolinona acetamida | |
| AR055592A1 (es) | Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace) | |
| AR061564A1 (es) | Derivados de isoindoles, composiciones farmaceuticas y usos | |
| AR048974A1 (es) | Derivados sustituidos del dioxido de oxazol-benzoisotiazol y composiciones farmaceuticas. | |
| AR110153A1 (es) | ÁCIDOS PROPIÓNICOS 3-SUSTITUIDOS COMO INHIBIDORES DE LA INTEGRINA aV | |
| AR070343A1 (es) | Piridinil amidas, un procedimiento para el tratamiento de la esquizofrenia en un mamifero y una composicion farmaceutica | |
| AR067646A1 (es) | Ariloxazoles sustituidos y su uso | |
| AR037907A1 (es) | Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |